Innovating Treatment for Addiction

Developing the first medication to prevent relapse and restore the brain's natural recovery system.

First target condition: stimulant use disorder (cocaine).

About Rafias

Building the Future of Addiction Treatment

Untitled (1000 x 1300 px) (1)_edited_edited.jpg

The Challenge

Addiction affects millions worldwide, and relapse during abstinence remains the hardest problem to solve. Stimulant use disorders have no FDA-approved medications, and behavioral therapies alone lead to high relapse rates and costly inpatient care.

Rafias is pioneering the first pharmacologic therapy engineered to prevent relapse during the abstinence phase, when the stakes are highest and current treatments fail.

Our Mission

We are developing the first safe and effective medication to prevent relapse in stimulant addiction. Our work advances neurobiology and chemistry to restore the brain’s capacity for sustained recovery.

Our Approach

Rafias targets Nr4a1, a transcription factor linked to addiction resilience. Through translational research at the University of Pennsylvania, we’re validating Nr4a1 as a first-in-class therapeutic target and building a commercially viable drug development pipeline.

NIH-Funded Innovation, Backed by Penn Research

$405K

NIH STTR Phase 1 Grant (Lead Identification)

$700K

NIH U18 Grant (Target Discovery)

$1M

NIH STTR Phase II (Prototype Development, pending)

A Global Crisis Demanding Scalable, Science-Driven Solutions

By The Numbers

5.2M

U.S. Cocaine Users

1.3M

With CUD Needing Treatment

$7.8B

Total Addressable Market

$5.5k

Annual Inpatient Rehab Cost

$6k/y

Estimated Cost of Rafias' Therapy

$18k

Lifetime Cost Savings Per Patient

For Investors

Our Focus Areas

Advancing science toward the first treatment for cocaine use disorder.

Target Discovery

Rafias discovered that Nr4a1, a transcription factor, is linked to addiction resilience. Activating Nr4a1 reduces drug-seeking behavior and restores neural balance in preclinical models.

Mouse model of cocaine addiction and transcriptomic discovery of Nr4a1. (2).png

Drug Development

We are designing next-generation Nr4a1 activators with improved stability and specificity. Each candidate undergoes rigorous potency, selectivity, and safety screening.

Mouse model of cocaine addiction and transcriptomic discovery of Nr4a1. (1).png

Translational Research

Preclinical studies confirm efficacy disorder confirm efficacy and safety benchmarks, bridging foundational neurobiology with therapeutic application.

Mouse model of cocaine addiction and transcriptomic discovery of Nr4a1. (4).png

Platform & Partnerships

Supported by NIH Small Business Funding and Penn's Center for Innovation, Rafias is building a first-in-class platform to deliver safe, effective addiction therapeutics to market.